Literature DB >> 20845513

p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival.

Kyung-Eun Lee1, Young-Seoub Hong, Byoung-Gwon Kim, Na-Young Kim, Kyoung-Mu Lee, Jong-Young Kwak, Mee-Sook Roh.   

Abstract

AIM: To analyze the association between the p73 G4C14-to-A4T14 polymorphism (a.k.a., the GC/AT variation) and colorectal cancer risk and survival in the Korean population, and to evaluate the relationships between p73 polymorphism and the p73 protein expression or clinicopathological characteristics of colorectal cancer.
METHODS: Three hundred and eighty-three histologically confirmed cases and 469 healthy controls, recruited at one teaching hospital in Pusan, Korea from 2001 and 2007, were genotyped for p73 G4C14-to-A4T14 by PCR with confronting two-pair primers (PCR-CTPP) and the expression profile of p73 in cancer tissues (n = 383) was analyzed by immunohistochemistry.
RESULTS: Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression model adjusted for age and gender. Compared with the GC/GC genotypes, the GC/AT and AT/AT genotypes were significantly associated with colorectal cancer risk (GC/AT vs GC/GC: OR = 1.46, 95% CI: 1.10-1.94; AT/AT vs GC/GC: 1.72, 0.98-3.03; P(trend) = 0.01). When stratified by age and gender, the association was restricted to those less than 60 years of age (GC/AT or AT/AT vs GC/GC: 2.22, 1.39-3.55) and male (GC/AT or AT/AT vs GC/GC: 1.91, 1.31-2.77). The expression of p73 was associated with invasion depth (P = 0.003) and advanced Duke's stage (P = 0.06) of colorectal cancer. The patients with the GC/GC genotype were associated with worse survival compared with those with the other genotypes (P = 0.02). However, no significant relationship was observed between the p73 G4C14-to-A4T14 polymorphism and p73 protein expression in cancer tissues.
CONCLUSION: Our results suggest that the p73 GC/AT polymorphism is associated with an increased colorectal cancer risk and survival in the Korean population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20845513      PMCID: PMC2941069          DOI: 10.3748/wjg.v16.i35.4448

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  p63 and p73 are required for p53-dependent apoptosis in response to DNA damage.

Authors:  Elsa R Flores; Kenneth Y Tsai; Denise Crowley; Shomit Sengupta; Annie Yang; Frank McKeon; Tyler Jacks
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

2.  p73 is up-regulated in a subset of hepatocellular carcinomas.

Authors:  N I Herath; M C Kew; V L Whitehall; M D Walsh; J R Jass; K K Khanna; J Young; L W Powell; B A Leggett; G A Macdonald
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

3.  p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma.

Authors:  Xiao-Feng Sun
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

4.  p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours.

Authors:  A Yang; N Walker; R Bronson; M Kaghad; M Oosterwegel; J Bonnin; C Vagner; H Bonnet; P Dikkes; A Sharpe; F McKeon; D Caput
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

5.  Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis.

Authors:  Hong-Ran Choi; John G Batsakis; Feng Zhan; Erich Sturgis; Mario A Luna; Adel K El-Naggar
Journal:  Hum Pathol       Date:  2002-02       Impact factor: 3.466

6.  Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer.

Authors:  M A Peters; M Janer; S Kolb; G P Jarvik; E A Ostrander; J L Stanford
Journal:  Prostate       Date:  2001-09-15       Impact factor: 4.104

Review 7.  TP53 family members and human cancers.

Authors:  Jean Bénard; Setha Douc-Rasy; Jean-Charles Ahomadegbe
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

8.  Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes.

Authors:  Akio Hiraki; Keitari Matsuo; Nobuyuki Hamajima; Hidemi Ito; Shunzo Hatooka; Motokazu Suyama; Tetsuya Mitsudomi; Kazuo Tajima
Journal:  Asian Pac J Cancer Prev       Date:  2003 Apr-Jun

9.  TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease.

Authors:  Quanyi Li; Eleni S Athan; Michelle Wei; Eric Yuan; Samuel L Rice; Jean-Paul Vonsattel; Richard P Mayeux; Benjamin Tycko
Journal:  BMC Med Genet       Date:  2004-06-02       Impact factor: 2.103

10.  A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma.

Authors:  B M Ryan; R McManus; J S Daly; E Carton; P W Keeling; J V Reynolds; D Kelleher
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

View more
  10 in total

1.  Association of p73 gene G4C14-A4T14 polymorphism and MDM2 gene SNP309 with non-small cell lung cancer risk in a Chinese population.

Authors:  Wen Li; Shuang Shuang Wang; Jing Deng; Jian Xin Tang
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

2.  Association of p73 G4C14-to-A4T14 polymorphism with non-small cell lung cancer risk.

Authors:  Shuang Shuang Wang; Xiang Qin Zhu; Shao DI Yang; Lin Li Dong; Wen Li; Jianxin Tang
Journal:  Oncol Lett       Date:  2015-06-04       Impact factor: 2.967

3.  p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China.

Authors:  Xin Zhou
Journal:  Med Oncol       Date:  2013-02-27       Impact factor: 3.064

4.  Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems.

Authors:  Yuqing Ma; Qiaoxin Li; Wenli Cui; Na Miao; Xia Liu; Wei Zhang; Chen Zhang; Jian Wang
Journal:  Diagn Pathol       Date:  2012-09-14       Impact factor: 2.644

5.  The Role of Genetic Polymorphisms in Nrf2 and P73 in Egyptian Women with Breast Cancer

Authors:  Nevin M Al Azhary; Mahmoud M Kamel; Yahia M Ismail; Amal A Mahmoud; Enas M Radwan
Journal:  Asian Pac J Cancer Prev       Date:  2016-11-01

6.  P73 G4C14-to-A4T14 polymorphism is associated with survival in advanced non-small cell lung cancer patients.

Authors:  Lei Ge; Yang Yang; Yifeng Sun; Wen Xu; Daru Lu; Bo Su
Journal:  Thorac Cancer       Date:  2017-01-30       Impact factor: 3.500

7.  TP73 G4C14-A4T14 polymorphism and cancer susceptibility: evidence from 36 case-control studies.

Authors:  Jialin Meng; Shuo Wang; Meng Zhang; Song Fan; Li Zhang; Chaozhao Liang
Journal:  Biosci Rep       Date:  2018-12-14       Impact factor: 3.840

8.  Case-control study on TP73 rs1801173 C > T gene polymorphism and susceptibility to gastric cancer in a Chinese Han population.

Authors:  Huiwen Pan; Xuyu Gu; Xiaoyan Wang; Zhenjun Gao; Guowen Ding; Chen Zou; Yu Fan
Journal:  BMC Med Genomics       Date:  2022-01-24       Impact factor: 3.063

9.  Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance.

Authors:  L Michael Carastro; Hui-Yi Lin; Hyun Y Park; Donghwa Kim; Selina Radlein; Kaia K Hampton; Ardeshir Hakam; Babu Zachariah; Julio Pow-Sang; Jong Y Park
Journal:  Prostate Cancer       Date:  2014-07-06

Review 10.  Oncogenic Intra-p53 Family Member Interactions in Human Cancers.

Authors:  Maria Ferraiuolo; Silvia Di Agostino; Giovanni Blandino; Sabrina Strano
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.